Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-522 in Cystic Fibrosis
NCT05668741Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 2 trial of vx-522 in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Feb 2023; status: completed.
02
Drugs
vx-522
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05668741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668741.